Li Shufang, Wang Yan, Xin Shizhen, Cao Jiancun
Graduate School, Tianjin Medical University, Tianjin 300070, China.
Zhongguo Fei Ai Za Zhi. 2012 Aug;15(8):465-70. doi: 10.3779/j.issn.1009-3419.2012.08.03.
This study aims to observe the changes in quality of life as well as the anxiety among lung cancer patients before and after chemotherapy. This work also aims to explore the effect of chemotherapy on quality of life and anxiety.
Fifty-eight lung cancer patients were evaluated based on clinical outcomes, EORTC QLQ-C30, and on SAS questionnaires before chemotherapy, one week after two courses of chemotherapy, and one week after four courses of chemotherapy.
Before chemotherapy, functioning scale, fatigue, and dyspnoea scores were high, the rate of anxiety was 56%, while the SAS score was 49.54±5.64. Anxiety was found to be positively correlated with insomnia (P<0.05). After two courses of chemotherapy, dyspnoea scores decreased, while insomnia and appetite loss scores increased. The difference was statistically significant (P<0.05). The rate of anxiety was 80%, and the SAS score was 52.48±6.10. The difference was statistically significant compared with that before chemotherapy (P<0.05). The SAS scores of patients with disease history were higher than those of patients without disease history (P<0.05). SAS score was found to be positively correlated with fatigue and dyspnoea (P<0.05). After four courses of chemotherapy, the physical, role, emotional, and social function scores decreased, while the nausea and vomiting, appetite loss, constipation, and financial impact scores increased. The difference was statistically significant (P<0.05). The anxiety rate was 72%, and the SAS score was 54.82±6.55. The difference was statistically significant (P<0.05). The SAS score was negatively correlated with KPS (P<0.05), significantly positively correlated with fatigue and insomnia (P<0.01), and positively correlated with constipation (P<0.05).
A number of patients have experienced symptom relief, but during chemotherapy, the patients had significant anxiety. Thus, quality of life decreased. The quality of life and emotions of lung cancer patients should be evaluated, and positive psychological intervention should be given to improve quality of life.
本研究旨在观察肺癌患者化疗前后生活质量的变化以及焦虑情况。本研究还旨在探讨化疗对生活质量和焦虑的影响。
对58例肺癌患者在化疗前、两疗程化疗后1周以及四疗程化疗后1周，依据临床疗效、欧洲癌症研究与治疗组织生活质量核心问卷（EORTC QLQ-C30）和焦虑自评量表（SAS）问卷进行评估。
化疗前，功能量表、疲劳及呼吸困难评分较高，焦虑发生率为56%，SAS评分为49.54±5.64。焦虑与失眠呈正相关（P<0.05）。两疗程化疗后，呼吸困难评分降低，而失眠及食欲减退评分升高。差异有统计学意义（P<0.05）。焦虑发生率为80%，SAS评分为52.48±6.10。与化疗前相比差异有统计学意义（P<0.05）。有病史患者的SAS评分高于无病史患者（P<0.05）。SAS评分与疲劳及呼吸困难呈正相关（P<0.05）。四疗程化疗后，身体、角色、情感及社会功能评分降低，而恶心呕吐、食欲减退、便秘及经济影响评分升高。差异有统计学意义（P<0.05）。焦虑发生率为72%，SAS评分为54.82±6.55。差异有统计学意义（P<0.05）。SAS评分与KPS呈负相关（P<0.05），与疲劳及失眠呈显著正相关（P<0.01），与便秘呈正相关（P<0.05）。
部分患者症状得到缓解，但化疗期间患者焦虑明显，生活质量下降。应评估肺癌患者的生活质量及情绪状态，并给予积极的心理干预以提高生活质量。
